Investor Presentaiton
3
IDEAYA Biosciences Highlights
Leading Precision Medicine Oncology focused biotechnology company advancing
transformative First-in-Class targeted and Synthetic Lethality (SL) therapies for cancer patients
Broad Pipeline of Key Emerging Targets
-
Ph 2/3 Registrational: Darovasertib (PKC) MUM
■
-
Ph 2: Darovasertib (Neo)Adjuvant Primary UM
2023 Target Milestones
Darovasertib (PKC) / Crizotinib – Registrational in MUM
-
Phase 2/3 Registrational Trial
-
Phase 2 Program Update including ctDNA Data (ESMO Q4 '23)
-
-
Ph 2: IDE397 (MAT2A)
Ph 1: IDE397 + AMG 193 (PRMT5MTA)
Ph 1: IDE161 (PARG)
Ph 1: GSK101 (IDE705) (Pol Theta Helicase)
Preclinical Lead Optimization: Werner Helicase
Pharma Collaborations with Pfizer (CTCSA), Amgen
(CTCSA), GSK (with ~$2B in potential milestones)
Balance Sheet of ~$510M to fund ops into 20271,2
NASDAQ: IDYA
(1) Includes aggregate of $510.1 M cash, cash equivalents and marketable securities as of June 30, 2023
(2) IDEAYA Form 10-Q dated August 10, 2023 as filed with the U.S. Securities and Exchange Commission
IND=Investigational New Drug
-
Darovasertib (PKC) - Phase 2 in Primary UM
Phase 2 in Neoadjuvant / Adjuvant UM (IST Update Q4 '23)
IDE397 (MAT2A) - Phase 1/2
Phase 2 Monotherapy Expansion in High-Priority Tumors
Phase 1 Amgen-Sponsored IDE397 + AMG 193
■ IDE161 (PARG) - Phase 1/2
-
Phase 1 Expansion in HRD Tumors (Program Updates H2'23)
■ GSK101 (IDE705) (Pol Theta Helicase) - Phase 1/2
Phase 1 GSK-Sponsored GSK101 + Niraparib (FPI Q4'23)
Werner Helicase
-
Development Candidate (Nomination H2 '23)
IDEA A
BIOSCIENCESView entire presentation